The Effect of Oral Carnosine Supplementation on Urine Microalbumin in Diabetic Nephropathy: A Randomized Controlled Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220226002

Enrollment

Registered

2022-02-26

Start date

2020-06-30

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy carnosine diabetic nephropathy urine microalbumin urine TGF-b

Interventions

Carnosine capsule(1g) 1 capsule oral bid (total 2g/d) for 12 weeks ,Placebo capsule 1 capsule oral bid for 12 weeks

Active Comparator Drug,Placebo Comparator No treatment

Carnosine ,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: age of 18 years old or older urine albumin-creatinine ratio (UACR) of 30 to 299 mg/g creatinine (Cr) stable dose of ACEIs or ARBs at least 3 months stable hemoglobinA1C (HbA1C) within 3 months

Exclusion criteria

Exclusion criteria: active infections CKD from nondiabetic cause advanced malignancy history of hypersensitivity to protein nutrients problems with nutrient absorption of the gastro-intestinal tract liver disease

Design outcomes

Primary

Measure	Time frame
urine microalbumin at 12 weeks after intervention UACR	—

Secondary

Measure	Time frame
urine TGF-Beta at 12 weeks after intervention ELISA	—

Countries

Thailand

Contacts

Public ContactChanon Yooyen

Phramongkutklao Hospital

chanon.rtn@gmail.com0908870473

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026